NOS1AP (Nitric Oxide Synthase Adaptor Protein)
Details
NOS1AP encodes nitric oxide synthase adaptor protein, a scaffolding protein that interacts with neuronal nitric oxide synthase (nNOS/NOS1). Originally identified in the brain, NOS1AP was identified as a cardiac arrhythmia modifier through genome-wide association studies (GWAS) linking common noncoding variants to QT interval duration in the general population. It is now the most robustly validated genetic modifier of LQTS severity and extends as a modifier to drug-induced LQTS and arrhythmic risk in acute myocardial infarction.
Key Facts
Gene Function and Background
- NOS1AP is a scaffolding protein for nNOS. Its exact mechanism of action in cardiac repolarisation is not fully established. (sources/modifier-genes-scd-ehj-2018, rating: high)
- NOS1AP variants were first identified as QT interval determinants in general population GWAS — not through arrhythmia disease candidate gene approaches. (sources/modifier-genes-scd-ehj-2018)
- Mechanistic confirmation in hiPSC-CMs and mouse models (Dababneh 2025): NOS1AP variants modulate cardiac repolarization via regulation of NOS1 (neuronal nitric oxide synthase) activity on cardiac ion channels — confirmed in both hiPSC-derived cardiomyocytes and mouse models. This validates a biological mechanism downstream of NOS1AP: NOS1-derived nitric oxide modulates the function of repolarizing ion channel complexes, providing a plausible pathway through which NOS1AP variants alter APD and arrhythmic risk. (sources/gwas-arrhythmias-cmp-genes-2025, rating: high)
NOS1AP as LQTS Modifier
- In the South African LQT1 founder population (KCNQ1-A341V, ~200 mutation carriers), two common noncoding NOS1AP variants were associated with elevated risk of life-threatening arrhythmias — the first demonstration that a GWAS-derived QT modifier also modifies LQTS severity. (sources/modifier-genes-scd-ehj-2018)
- Findings validated in heterogeneous LQTS populations (multiple genotype backgrounds) and in a Netherlands LQT2 cohort. The breadth of replication across different primary mutations and populations establishes NOS1AP as the most robustly validated LQTS modifier gene. (sources/modifier-genes-scd-ehj-2018)
- NOS1AP variants are also associated with the risk of developing drug-induced long QT syndrome, extending its modifier role beyond congenital LQTS. (sources/modifier-genes-scd-ehj-2018)
NOS1AP in AMI-VF
- NOS1AP variants were associated with higher SCD risk in white adults and in the Rotterdam Study (the latter not exclusively AMI). This suggests NOS1AP modifier effects generalise across arrhythmic contexts — from congenital LQTS to acquired/ischaemic arrhythmia. (sources/modifier-genes-scd-ehj-2018)
Clinical Implication
- LQTS mutation carriers who also carry NOS1AP risk alleles may require more vigilant arrhythmia monitoring or more aggressive prophylactic therapy compared to mutation carriers without these variants. (sources/modifier-genes-scd-ehj-2018)
- Prospective validation studies are needed before NOS1AP genotyping enters routine LQTS risk stratification algorithms. (sources/modifier-genes-scd-ehj-2018)
Contradictions / Open Questions
- NOS1AP biology paradox — partially resolved: NOS1AP risk alleles (associated with longer QT in humans) correlate with higher NOS1AP expression in human ventricular myocardium (cis-regulatory enhancer variants, pacemaker/ICD lead extraction studies). However, NOS1AP overexpression in guinea pig and rat cardiomyocytes shortens APD — the opposite direction — and NOS1AP suppression in zebrafish also shortens APD. Dababneh 2025 confirmed NOS1AP modulates repolarisation via NOS1 activity regulation in hiPSC-CMs and mouse models, establishing a mechanistic pathway; however, the directional discrepancy between rodent/zebrafish models and human data remains unreconciled. Human iPSC-CM models may be the most appropriate platform to resolve the human-specific direction of effect. (sources/modifier-genes-scd-ehj-2018, sources/gwas-arrhythmias-cmp-genes-2025)
- Population association vs. individual prediction: NOS1AP was validated as a risk-modifying allele at the population level. Applying population-level associations to clinical decisions for individual patients requires prospective validation in LQTS cohorts, which has not been completed. (sources/modifier-genes-scd-ehj-2018)
Connections
- Related to concepts/Modifier-Genes
- Related to entities/Long-QT-Syndrome
- Related to entities/KCNQ1
- Related to entities/KCNH2
- Related to concepts/Polygenic-Risk-Score
- Related to concepts/Sudden-Cardiac-Death
- Related to concepts/GWAS-Cardiac-Genetics
- Related to sources/modifier-genes-scd-ehj-2018
- Related to sources/gwas-arrhythmias-cmp-genes-2025